Home
About
Overview
Sharing Data
ORCID
Help
History (6)
Principal Investigator
Rapidly fatal familial histiocytosis associated with eosinophilia and primary immunological deficiency.
Safety of Polysorbate 80 in the Oncology Setting.
Sec24 interaction is essential for localization and virulence-associated function of the bacterial effector protein NleA.
Successful treatment of Zoon's vulvitis with high potency topical steroid.
See All 6 Pages
Find People
Find Everything
Login
to edit your profile (add a photo, awards, links to other websites, etc.)
Edit My Profile
My Person List (
0
)
Return to Top
Search Result Details
Back to Search Results
This page shows the details of why an item matched the keywords from your search.
Search Results
Ji, Yuan
One or more keywords matched the following items that are connected to
Ji, Yuan
Item Type
Name
Concept
Clinical Trials, Phase I as Topic
Concept
Clinical Trials, Phase II as Topic
Academic Article
Bayesian dose-finding in phase I/II clinical trials using toxicity and efficacy odds ratios.
Academic Article
Dose--schedule finding in phase I/II clinical trials using a Bayesian isotonic transformation.
Academic Article
Dose-finding in phase I clinical trials based on toxicity probability intervals.
Academic Article
Modified toxicity probability interval design: a safer and more reliable method than the 3 + 3 design for practical phase I trials.
Academic Article
A decision-theoretic phase I-II design for ordinal outcomes in two cycles.
Academic Article
Toxicity and Efficacy Probability Interval Design for Phase I Adoptive Cell Therapy Dose-Finding Clinical Trials.
Academic Article
A Bayesian interval dose-finding design addressingOckham's razor: mTPI-2.
Academic Article
R-TPI: rolling toxicity probability interval design to shorten the duration and maintain safety of phase I trials.
Academic Article
The i3+3 design for phase I clinical trials.
Academic Article
Bayesian continual reassessment method for dose-finding trials infusing T cells with limited sample size.
Academic Article
Monitoring late-onset toxicities in phase I trials using predicted risks.
Search Criteria
Clinical Trials Phase III as Topic